The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Matthew Ringel, Electra Paskett, Zihai Li named deputy directors at OSUCCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Matthew Ringel

Electra Paskett

Zihai Li

Matthew Ringel, Electra Paskett, and Zihai Li were named deputy directors at The Ohio State University Comprehensive Cancer Center. They will report to OSUCCC Director Raphael Pollock. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Lifileucel shrinks tumors in mNSCLC in phase II trial

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
In Brief

OSU—James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control

A clinic at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Immuno-Oncology Institute aims to help manage the autoimmune side effects of immunotherapy-based cancer treatment and allow patients to live the fullest life possible both during cancer treatment and long-term as a survivor.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account